billHR1062Event Thursday, February 6, 2025Analyzed

Growing and Preserving Innovation in America Act of 2025

Bullish
Impact4/10

Summary

HR1062, introduced Feb 2025, would permanently lock in higher FDII/GILTI tax deductions for US corporations, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This is a direct net-income booster for US multinationals with large international IP revenue streams. The bill is in early committee stage; market impact is structural but delayed pending passage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR1062 prevents a 2026 tax increase on US companies' foreign IP income, directly improving after-tax net income for major tech, pharma, and consumer multinationals
  • 2.Bill is in early stage (referred to committee Feb 2025) — no imminent passage; structural impact is conditional on full legislative process
  • 3.No direct spending; pure tax code preservation — estimated annual benefit ranges from $150M (KO) to $2B (MSFT) per company
  • 4.Recent stock price strength in GOOGL, NVDA, AMZN, INTC reflects broader market trends, not bill-driven catalysts yet

Market Implications

The primary implication is that HR1062's passage would structurally increase after-tax earnings for all major US multinationals with significant foreign IP income. Microsoft ($429.25), Alphabet ($349.78), and Apple ($270.71) are the largest beneficiaries by absolute dollar impact due to their massive foreign revenue bases. NVIDIA ($213.17, +5.27% 7-day) and Intel ($84.52, +29.49% 7-day) have stronger momentum but would see smaller absolute tax benefits. Consumer staples PG ($149.17, +4.42% 7-day) and KO ($78.35, +4.98% 7-day) also benefit from their global brand IP structures. The market has not yet priced in this bill's probability given its early stage — any committee advancement would trigger incremental positive price discovery in these names.

Full Analysis

HR1062 (Growing and Preserving Innovation in America Act of 2025) was introduced by Rep. Feenstra (R-IA) on February 6, 2025, and referred to the House Ways & Means Committee — an early-stage bill with 7 cosponsors. The bill makes permanent the current higher deduction rates (37.5% for FDII, 50% for GILTI) that are scheduled to drop in 2026 to 21.875% and 37.5% respectively. This is a tax preservation bill, not a new spending authorization — no direct funding amount is allocated. The mechanism is a pure tax code change that prevents a scheduled increase in the effective tax rate on foreign-derived intangible income for US corporations. The money trail is clear: for companies like Microsoft, Apple, Alphabet, and NVIDIA with substantial patent, software, and IP-based income from foreign markets, this bill preserves an effective tax rate of ~13.125% on foreign IP income rather than the scheduled ~16.4% starting in 2026. The benefit is direct after-tax margin expansion. Real market data shows mixed short-term performance for beneficiaries: MSFT (-0.85% 7-day) and AAPL (-0.9%) have dipped slightly, while GOOGL (+3.08%), NVDA (+5.27%), and INTC (+29.49%) have rallied strongly. The 30-day trends are broadly up across tech (MSFT +20.32%, GOOGL +27.5%, AMZN +30.28%, NVDA +27.25%, INTC +95.97%), reflecting broader market momentum rather than this bill specifically — it's too early-stage to have driven price action. Structural winners are US-headquartered multinationals with high GAAP profitability from foreign IP — primarily big tech, pharma, and branded consumer goods. The legislative path requires Ways & Means Committee markup, House floor vote, Senate consideration, and White House signature. As an early-stage bill with a Republican sponsor in a Republican-controlled House (119th Congress), it has alignment with the majority party's policy priorities, but passage is not guaranteed. The bill's permanence provision makes it a higher-impact structural change vs. a temporary extension. Executive actions provided (Presidential Memoranda on petroleum production and Air Force training) are not directly relevant to this tax bill and do not amplify or conflict with HR1062's provisions.

Market Impact Score

4/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.